RATIONALE: Diagnosing autoreactivity in chronic spontaneous urticaria (CSU) can predict a more prolonged disease course, higher disease activity, need for higher doses of anti-histamines and the responsiveness to cyclosporin A and omalizumab. The BAT can identify these patients but is not widely available. Finding a combination of clinical data that helps identify these patients is clinically relevant. We aimed to analyse the clinical and laboratorial characteristics of BAT positive CSU patients and identify predictors of BAT positivity. METHODS: Cross-sectional study of 64 patients with CSU, with a 1-year follow-up. Data were analysed using SPSS: Student's t test, Chi-square test, Kappa coefficient, Odds Ratio, multivariable logistic regression model and ROC curve. RESULTS: Twenty-five patients were BAT negative and 39 were BAT positive. Six characteristics were significantly more frequent in the BAT positive group (p<0.05): a positive ASST, a UAS7> _16, presence of angioedema, presence of nocturnal symptoms, symptoms for >5 days/ week, and presence of anti-TG/TPO autoantibodies. This group also had a tendency for worse DLQI and UCT scores, a higher number of patients requiring therapy with omalizumab and had a lower total serum IgE. The combination of these characteristics showed good sensitivity and specificity at identifying BAT positive patients and statistical analysis demonstrated that they had a good discriminant power (area under the ROC curve 0.836). CONCLUSIONS: CSU patients can be divided into two distinct subsets using the BAT. BAT positive patients have a more severe disease and are strongly associated with 6 clinical characteristics that may be used in the future as surrogate markers. (CIU). There is limited data on the long-term use of omalizumab for CIU, particularly with regards to frequency, dosing, and potential for tapering its use. METHODS: With an IRB-approved protocol, 48 adult patients diagnosed with chronic urticaria and treated with omalizumab were identified in the electronic medical record (EMR). 21 patients were excluded for having diagnosis of mastocytosis and/or less than 1 year of omalizumab use. Of the remaining 27 patients, clinic notes from the Allergy clinic were accessed to collect the following data: age, sex, BMI, omalizumab starting and current dose, frequency and use of additional medications before and after starting omalizumab. RESULTS: The 27 patients with CIU on omalizumab for at least 1 year (average duration 38 months) included 5 males and 22 females with an average age of 48 years. 70% of the patients in this study were obese (BMI > _ 36). The average starting cumulative dose of omalizumab usage was 320 mg/4 weeks and the average current cumulative dose of omalizumab usage was 299 mg/4 weeks. 21 patients (81%) decreased or remained on the same dose of omalizumab. Overall, all patients had complete (85%) or almost complete (15%) urticaria symptom control. CONCLUSIONS: The majority of patients in this study remained on the same or decreased cumulative dosage of omalizumab for multiple years. All patients achieved complete or almost complete control of symptoms, suggesting an opportunity for tapering omalizumab dose and frequency.
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